Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) is 60.53% higher on its value in year-to-date trading and has touched a low of $9.00 and a high of $19.09 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CNTA stock was last observed hovering at around $13.56 in the last trading session, with the day’s gains setting it 0.47%.
Currently trading at $14.03, the stock is 7.32% and 8.56% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.22 million and changing 3.47% at the moment leaves the stock -7.58% off its SMA200. CNTA registered -16.24% loss for a year compared to 6-month loss of -17.52%. The firm has a 50-day simple moving average (SMA 50) of $12.9242 and a 200-day simple moving average (SMA200) of $15.180025.
The stock witnessed a 17.70% gain in the last 1 month and extending the period to 3 months gives it a 24.38%, and is 6.53% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.31% over the week and 5.52% over the month.
Centessa Pharmaceuticals plc ADR (CNTA) has around 77 employees, a market worth around $1.87B and $15.06M in sales. Profit margin for the company is -1483.64%. Distance from 52-week low is 55.89% and -26.51% from its 52-week high. The company has generated returns on investments over the last 12 months (-44.36%).
The EPS is expected to grow by 38.48% this year
164.0 institutions hold shares in Centessa Pharmaceuticals plc ADR (CNTA), with institutional investors hold 94.89% of the company’s shares. The shares outstanding are 133.55M, and float is at 84.74M with Short Float at 5.27%. Institutions hold 94.42% of the Float.
The top institutional shareholder in the company is MEDICXI VENTURES MANAGEMENT (JERSEY) LTD with over 19.96 million shares valued at $180.27 million. The investor’s holdings represent 18.233 of the CNTA Shares outstanding. As of 2024-06-30, the second largest holder is GENERAL ATLANTIC, L.P. with 9.68 million shares valued at $87.43 million to account for 8.8427 of the shares outstanding. The other top investors are ECOR1 CAPITAL, LLC which holds 5.71 million shares representing 5.2191 and valued at over $51.6 million, while FIRST LIGHT ASSET MANAGEMENT, LLC holds 4.3662 of the shares totaling 4.78 million with a market value of $43.17 million.
Centessa Pharmaceuticals plc ADR (CNTA) Insider Activity
The most recent transaction is an insider sale by Weinhoff Gregory M, the company’s Chief Business Officer. SEC filings show that Weinhoff Gregory M sold 10,000 shares of the company’s common stock on Jun 25 ’25 at a price of $13.86 per share for a total of $0.14 million. Following the sale, the insider now owns 0.12 million shares.
Centessa Pharmaceuticals plc ADR disclosed in a document filed with the SEC on Jun 24 ’25 that HUSSAIN IQBAL J (General Counsel) sold a total of 12,000 shares of the company’s common stock. The trade occurred on Jun 24 ’25 and was made at $14.02 per share for $0.17 million. Following the transaction, the insider now directly holds 0.11 million shares of the CNTA stock.
Still, SEC filings show that on Jun 24 ’25, Accardi Mario Alberto (President, Orexin Program) disposed off 15,000 shares at an average price of $14.00 for $0.21 million. The insider now directly holds 216,485 shares of Centessa Pharmaceuticals plc ADR (CNTA).
